

MicroRNA hsa-miR-1301-3p regulates human *ADH6*, *ALDH5A1* and *ALDH8A1* in the ethanol-acetaldehyde-acetate metabolic pathway

Xubing Wang<sup>1\*</sup>, Yanjie Zhao<sup>1\*</sup>, Jiao Luo<sup>1</sup>, Lin Xu<sup>1</sup>, Xinmei Li<sup>1</sup>, Yuan Jin<sup>1</sup>, Chuanhai Li<sup>1</sup>, Meiyao Feng<sup>1</sup>, Ying Wang<sup>1</sup>, Jing Chen<sup>1</sup>, Yufei Hou<sup>1</sup>, Qianwen Zhao<sup>1</sup>, Jinquan Zhao<sup>1</sup>, Baitang Ning<sup>2</sup>, Yuxin Zheng<sup>1</sup>, and Dianke Yu<sup>1#</sup>

<sup>1</sup>School of Public Health, Qingdao University, Qingdao, China.

<sup>2</sup>National Center for Toxicological Research, US Food and Drug Administration.

#Corresponding Author:

*E-mail address: dianke.yu@qdu.edu.cn*

(1) **Running Title:** hsa-miR-1301-3p regulates *ADH6*, *ALDH5A1*, and *ALDH8A1*

(2) **Corresponding author:**

Name: Dianke Yu

Address: School of Public Health, Qingdao University, 38 Dengzhou Road,  
Qingdao, Shandong 266021, China.

Telephone: 86-13361480538

Email: dianke.yu@qdu.edu.cn

(3) Text pages: 30

Number of tables: 1

Number of figures: 5

Number of references: 56

Number of words in the Abstract: 199

Number of words in the Introduction: 709

Number of words in the Discussion: 1382

(4) **List of abbreviations:**

ADHs, alcohol dehydrogenases; ALD, alcoholic liver disease; ALDHs, aldehyde dehydrogenases; ANOVA, analysis of variance; C/EBP, CCAAT/enhancer binding proteins; DMEs, drug metabolizing enzymes; DMEM, Dulbecco's Modified Eagle medium; FBS, fetal bovine serum; FREMSA, fluorescent-based RNA electrophoretic mobility shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HEPES, N-2-hydroxyethylpiperazine-N-2'-ethanesulfonic acid; miRNA, microRNA; MREs, miRNA response elements; NAD, nicotinamide adenine dinucleotide; NC, negative control; qRT-PCR, quantitative real-time PCR; RIPA, radioimmunoprecipitation assay; RPKM,

reads per kilobase per million mapped reads; SREBP-1c, sterol regulatory element-binding protein-1c; UTR, untranslated region.

## Abstract

Alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs) are vital enzymes involved in the metabolism of a variety of alcohols. Differences in the expression and enzymatic activity of human ADHs and ALDHs correlate with individual variability in metabolizing alcohols and drugs and in the susceptibility to alcoholic liver disease (ALD). MicroRNAs (miRNAs) function as epigenetic modulators to regulate the expression of drug metabolizing enzymes (DMEs). To characterize miRNAs that target ADHs and ALDHs in human liver cells, we carried out a systematic bioinformatics analysis to analyze free energies of the interaction between miRNAs and their cognate sequences in *ADH* and *ALDH* transcripts, and then calculated expression correlations between miRNAs and their targeting *ADH* and *ALDH* genes using a public database. Candidate miRNAs were selected to evaluate bioinformatic predictions using a series of biochemical assays. Our results showed that 11 miRNAs have the potential to modulate the expression of 2 *ADH* and 7 *ALDH* genes in the human liver. We found that hsa-miR-1301-3p suppressed the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* in liver cells and blocked their induction by ethanol. In summary, our results revealed that hsa-miR-1301-3p plays an important role in ethanol metabolism by regulating *ADH* and *ALDH* gene expression.

**Key words:** hepatotoxicity, ethanol metabolizing enzyme, hsa-miR-1301-3p, *ADH6*, *ALDH5A1*, *ALDH8A1*

## Significance statement:

Systematic bioinformatics analysis showed that 11 miRNAs might play regulatory

roles in the expression of 2 *ADH* and 7 *ALDH* genes in the human liver. Experimental evidences proved that hsa-miR-1301-3p suppressed the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* in liver cells and decreased their inducibility by ethanol.

## Introduction

Upon consumption, 80% of ethanol is absorbed in the upper small intestine and then transported to other organs. The liver is the primary site of ethanol metabolism. Excessive ethanol consumption is a common cause of liver injury and alcoholic liver disease (ALD) that encompasses liver manifestations, including fatty liver, fibrosis, cirrhosis, or even hepatocellular carcinoma (Adachi and Brenner, 2005; Tilg and Day, 2007). In China, the prevalence of ALD has increased considerably in recent years, which is correlated with an increase in alcohol consumption (Heo et al., 2019).

The major two-step oxidative metabolic pathway for ethanol begins with its oxidation to acetaldehyde with further oxidation to produce acetic acid (Dinis-Oliveira, 2016). The oxidation of ethanol to acetaldehyde is catalyzed by alcohol dehydrogenases (ADHs) and CYP2E1; this constitutes the rate-limiting step of ethanol metabolism. Subsequently, acetaldehyde is further oxidized to acetic acid by aldehyde dehydrogenases (ALDHs) using nicotinamide adenine dinucleotide (NAD) as the cofactor, followed by elimination of the acetic acid end product through urine.

Obvious individual variability in ethanol metabolism is noted among humans, partially attributed to differences in genetic background, age, sex, and health status (Liangpunsakul et al., 2016). For example, studies showed that functional genetic variants in *ADH* and *ALDH* genes affected the activities or the expression levels of ethanol metabolizing enzymes, thus varying the catabolic rate of ethanol (Birley et al., 2009; Hartwell and Kranzler, 2019).

ADH and ALDH proteins represent two distinct families of enzymes. Specifically, the ADH family consists of multiple isozymes and allozymes that are divided into five (I-

V) classes (Cederbaum, 2012) while the ALDH superfamily includes 19 functionally-related family members (Vasiliou and Nebert, 2005). In addition to the primary function of ADHs and ALDHs members (especially ADHs and ALDH2) in ethanol metabolism, ADHs and ALDHs are also involved in metabolizing a large spectrum of biologically important alcohols and aldehydes, including drugs (Jelski and Szmitkowski, 2008).

The complexity of regulatory mechanisms underlying ethanol metabolism is not fully understood. Epigenetic regulatory mechanisms, including DNA methylation, non-coding RNAs, and histone modification, provide novel genotype-independent mechanisms to modulate gene expression, contributing to individual variability in the metabolism and toxicity of ethanol and other chemicals (Davison et al., 2009; McDaniel et al., 2014; Meng et al., 2012; Moss and Wallrath, 2007; Rodenhiser and Mann, 2006). The microRNAs (miRNA), a class of non-coding single-stranded RNA molecules typically about 22 nucleotides in length, are well recognized as important epigenetic mediators that regulate the expression of drug metabolizing enzymes (DMEs) and nuclear receptors (Dluzen and Lazarus, 2015; Nakajima and Yokoi, 2011; Song and Wang, 2008; Yu, 2009). MiRNAs bind to the mRNA transcripts of target genes by partial sequence complementarity to miRNA response elements (MREs) that are most often located in the 3'- untranslated region (UTR) of target transcripts. Interactions between miRNAs and MREs generally result in either the enhanced degradation of mRNA target transcripts or decreased efficiency of translation. Previous studies showed that ALDH5A1 expression is suppressed by the miRNA hsa-miR-29a-3p and that CYP2E1 expression is modulated by multiple miRNAs (Wang et

al., 2017; Yu et al., 2015c). Specifically, miR-378a-5p and miR-214-3p bind to the 3'-UTR of *CYP2E1* mRNA transcripts, causing decreased CYP2E1 protein expression and enzymatic activity (Mohri et al., 2010; Wang et al., 2017), while miR-552 suppresses CYP2E1 protein production by interacting with both the 3'-UTR and the promoter region of *CYP2E1* (Miao et al., 2016). Although a few studies have reported associations between miRNAs and *CYP2E1* and *ALDH5A1* genes, to our knowledge no systematic analysis has been carried out to elucidate the functional roles of miRNAs in the expression of other genes in the catabolic pathway of alcohol, notably other *ADH* and *ALDH* genes expressed in the liver.

In this study, we selected the *ADH* and *ALDH* genes expressed in the human liver and predicted potential miRNA binding sites located in the 3'-UTRs of these target genes via *in silico* analyses. Further, we identified hsa-miR-1301-3p as a candidate regulatory miRNA associated with ethanol metabolism. Finally, we tested the regulatory role of hsa-miR1301-3p on the suppression of *ADH6*, *ALDH5A1*, and *ALDH8A1* using a series of *in vitro* and *in vivo* experimental approaches. Our results provided new clues to elucidate the epigenetic regulatory mechanisms influencing the expression of ethanol metabolizing genes, thus adding a new layer of information towards understanding the interindividual variability in ethanol-induced liver injury and ALDs.



## Materials and methods

### Chemicals and Reagents

HepG2, Huh7, and 293T cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The hsa-miR-1301-3p mimic and miRNA negative control (NC) were purchased from Ribo Life Science (Shanghai, China). All oligonucleotides and primers used in our study were obtained from Sangon Biotech (Shanghai, China). All reporter gene vectors were produced by Generay Biotech (Shanghai, China). Rabbit anti-human antibodies against ADH6, ALDH5A1, and ALDH8A1 proteins, and mouse anti-human antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from Abcam (Cambridge, MA). Dual-Luciferase Reporter 1000 Assay System and TRIzol Reagent were purchased from Promega (Madison, WI). QuantiTect Reverse Transcription kit and Quanti Fast TB Green RT-PCR kit were obtained from Qiagen (Valencia, CA). NCode™ miRNA First-Strand cDNA Synthesis kit, Radioimmunoprecipitation assay (RIPA) buffer, and Lipofectamine 2000 reagent were purchased from Life Technologies (Carlsbad, CA). Odyssey™ Western Blotting Kit was purchased from LI-COR Biosciences (Lincoln, NE). All other reagents were of analytical grade.

### *In silico* analyses

Nine *ADH* and 15 *ALDH* genes (Yang et al., 2013) were screened using mRNA data in 98 human liver tissues from The Cancer Genome Atlas (TCGA) database (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>) to select the alcohol-metabolizing enzymes expressed in human liver. The miRNAs potentially targeting alcohol metabolizing genes were predicted using

the miRTar.human database (<http://mirtar.mbc.nctu.edu.tw/human/>), and the free energy of miRNA:mRNA duplexes was calculated by RNAhybrid algorithm (<http://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid>), respectively. The correlations between alcohol metabolism genes and miRNAs were calculated by Pearson correlation analysis, based on their RNA levels in liver tissues from TCGA database.

### **Cell Culture, transfection, and ethanol treatments**

HepG2, Huh7, and 293T cells were cultured in Dulbecco's Modified Eagle (DMEM) medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified 5% CO<sub>2</sub> atmosphere. All cell lines were used at less than 10 passages at the time of the study.

The hsa-miR-1301-3p mimic and miRNA NC were transiently transfected into HepG2 and Huh7 cells at the final concentration of 20 nmol/L using Lipofectamine 2000 reagent. Total RNAs and proteins were extracted at 24h or 48h after transfection experiments. In ethanol exposure experiments, HepG2 and Huh7 cells transfected with miRNA mimics were cultured for 24h, treated with 50 mM ethanol for another 24h, and then harvested to obtain total RNAs and proteins for subsequent analyses. All experiments were carried out at least three times.

### **Fluorescent-based RNA electrophoretic mobility shift assay (FREMSA)**

oligonucleotides and primers used in our study were obtained from Sangon Biotech (Shanghai, China), and their sequences were listed in **Supplemental Table 1**. The oligonucleotide for hsa-miR-1301-3p was dye-miR-1301-3p, which was synthesized and 5'-modified using DyLight 800 dye. The RNA oligonucleotides corresponding to the MREs of hsa-miR-1301-3p resident in 3'-UTR of *ADH6*, *ALDH5A1*, and *ALDH8A1*

were 5'-modified using Cy5.5 dye, and designated as dye-ADH6, dye-ALDH5A1, and dye-ALDH8A1, respectively. In addition, 50-fold molar excesses of unlabeled oligonucleotides for negative control were included in competition assays.

FREMSA was carried out according to the protocol described in our previous report (Yu et al., 2020). Briefly, 200 fmols dye-miR-1301-3p and cognate dye-ADH6, dye-ALDH5A1, and dye-ALDH8A1 oligonucleotides were mixed in basic buffer containing 10 mM N-2-hydroxyethylpiperazine-N-2'-ethanesulfonic acid (HEPES) Buffer (pH 7.3), 0.5% glycerol, 20 mM KCl, and 10 mM MgCl<sub>2</sub>, respectively. The mixtures were incubated for 20 min at room temperature, and then separated by 10% native polyacrylamide gel electrophoresis at 4°C. Interaction signals were detected using the Odyssey CLx Infrared Imaging System (LI-COR Biosciences).

### **Luciferase reporter gene assays**

The core 3'-UTRs containing the MREs of hsa-miR1301-3p located at the 3'-UTRs of *ADH6*, *ALDH5A1*, and *ALDH8A1* were synthesized chemically and subcloned into the pMirGlo system, and designated as ADH6-WT, ALDH5A1-WT, and ALDH8A1-WT, respectively, to create wild-type reporter gene vectors. Further, the mutant sequences that containing mutations in the MREs of hsa-miR1301-3p in *ADH6*, *ALDH5A1*, and *ALDH8A1*, which obviously increased free energy of miRNA:mRNA duplexes, were synthesized, subcloned into the pMirGlo system, and designated as ADH6-Mut, ALDH5A1-Mut, and ALDH8A1-Mut, respectively. All resultant constructs were sequenced to confirm their authenticity.

293T cells were seeded into 96-well plates at a density of  $3 \times 10^4$  cells/well and cultured till reaching approximately 80% confluence. Cells were transfected with

constructed reporter gene vectors (100 ng/well), together with hsa-miR-1301-3p mimics (final concentration: 50 nmol/L) or miRNA NC (final concentration: 50 nmol/L), using the Lipofectamine 2000 reagent. Both *Firefly* and *Renilla* luciferase activities were measured at 24h after transfection using the Dual-Luciferase Reporter 1000 Assay System, and transfection efficiencies were normalized to *Renilla* luciferase activity. Three independent experiments were conducted in triplicate.

### **RNA extraction and quantitative real-time PCR (qRT-PCR)**

The TRIzol Reagent was used to extract total RNAs from HepG2 and Huh7 cells. Reverse transcription reactions of mRNA or miRNA were conducted using QuantiTect Reverse Transcription kit, or NCode™ miRNA First-Strand cDNA Synthesis kit, respectively. The qRT-PCR assays were carried out using Quanti Fast TB Green RT-PCR kit with the LightCycler® 480 Detection System (Roche, Basel, Switzerland) and the primer pairs ADH6-F with ADH6-R, ALDH5A1-F with ALDH5A1-R, ALDH8A1-F with ALDH8A1-R, GAPDH-F with GAPDH-R, miR1301-3p-F with the reverse primer supplemented in the NCode™ miRNA First-Strand cDNA Synthesis kit, and U6-F with U6-R were designed to detect RNA levels for *ADH6*, *ALDH5A1*, *ALDH8A1*, *GAPDH*, hsa-miR-1301-3p, and the small nuclear RNA U6 control, respectively. The fold changes for *ADH6*, *ALDH5A1*, or *ALDH8A1* mRNA levels were calculated relative to *GAPDH*, while the fold change of hsa-miR-1301-3p was relative to snRNA U6 (Jiang et al., 2005). All experiments were carried out at least three times.

### **Western blotting**

RIPA buffer was used to extract total proteins from HepG2 or Huh7 cells. Western blotting assays were carried out using the Odyssey™ Western Blotting Kit, and

analyzed using the Odyssey CLx Infrared Imaging System. All experiments were carried out at least three times.

### **statistical analyses**

One-way analysis of variance (ANOVA) on ranks test was used to test the differences between subgroups in luciferase assays, and RNA or protein experiments, respectively. Data were shown as mean $\pm$ SD in the bar graphs, and *P* values of 0.05 were used as the cutoffs for statistical significance.

## Results

### Selection of miRNAs potentially targeting *ADH* and *ALDH* genes

RNA expression profiles of 9 *ADH* and 15 *ALDH* genes (Yang et al., 2013) in human liver tissues were obtained from the TCGA database. Among these genes, 7 *ADH* genes including *ADH1A*, *ADH1B*, *ADH1C*, *ADH4*, *ADH5*, *ADH6*, and *ADHFE1* (**Figure 1a**), and 14 *ALDH* genes including *ALDH1A1*, *ALDH1A2*, *ALDH1A3*, *ALDH1B1*, *ALDH2*, *ALDH3A1*, *ALDH3A2*, *ALDH3B1*, *ALDH4A1*, *ALDH5A1*, *ALDH6A1*, *ALDH7A1*, *ALDH8A1*, and *ALDH9A1* (**Figure 1b**), were observed to be variably expressed in human liver. *ADH1B* and *ALDH2* exhibited the highest expression, whereas *ADHFE1* and *ALDH1A2* were the ones with the lowest expression among the *ADH* and *ALDH* genes. Intriguingly, 5 *ADH* genes, including *ADH1A*, *ADH1B*, *ADH1C*, *ADH4*, and *ADH6*, and 4 *ALDH* genes, including *ALDH1A1*, *ALDH3A1*, *ALDH1A3*, and *ALDH8A1* presented a wide range of expression levels in liver samples, indicating the individual variability in ethanol metabolism.

We predicted the miRNAs that are potentially able to bind to the 3'-UTRs of 7 *ADH* genes and 14 *ALDH* genes using the miRTar.human database and then calculated the correlations between the expression of potential candidate miRNAs and the expression of their cognate targeting genes based on the liver expression dataset from TCGA database. As shown in **Table 1**, when the selection criteria were set as 1) the free energy of binding is smaller than  $-20.0$  kcal/mol and 2) the correlation coefficient between the expression of the miRNA and the expression of its target gene is smaller than  $-0.25$  ( $r < -0.25$ ) (Yu et al., 2015c), 11 mature miRNAs were considered as potential epigenetic modulators of *ADH4*, *ADH6*, *ALDH1A3*, *ALDH1B1*,

*ALDH3A2*, *ALDH4A1*, *ALDH5A1*, *ALDH8A1*, and *ALDH9A1*, respectively.

Compared to other miRNAs, hsa-miR-1301-3p, hsa-miR-330-5p, and hsa-miR-93-5p showed stronger negative correlations ( $r < -0.4$ ) (Akoglu, 2018), with the *ADH* or *ALDH* genes. Among which, hsa-miR-1301-3p exhibited the highest inverse correlations with mRNAs for *ALDH8A1* ( $r = -0.480$ ), *ADH6* ( $r = -0.469$ ), and *ALDH5A1* ( $r = -0.459$ ) and relatively strong binding affinities with its cognate MRE targets resident in these genes, suggesting its increased regulatory efficiency over the ethanol metabolism process. We then selected hsa-miR-1301-3p and its target genes, including *ADH6*, *ALDH5A1*, and *ALDH8A1*, for focused experiments to test the reliability of miRNA-gene interaction predictions made using bioinformatics (**Table 1**).

#### **hsa-miR-1301-3p interacted with *ADH6*, *ALDH5A1*, and *ALDH8A1* transcripts**

FREMSAs were applied to show the direct interactions between hsa-miR-1301-3p and its cognate mRNA targets *in vitro* (**Figure 2**). A strong band formed by dimeric dye-miR-1301-3p was observed in the absence of any targets (**Figure 2a, 2b, and 2c, lane 1**), due to the potential interactions among the dye-miR-1301-3p oligonucleotides ( $-20.2$  kcal/mol, **Supplemental Figure 1**). When the dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* oligonucleotide were added, the dye-miR-1301-3p displayed the mobility shift (the top band in **Figure 2a, 2b, and 2c, lane 3**) and the bands formed by dimeric dye-miR-1301-3p were significantly reduced, respectively, because the mRNA oligonucleotides have the stronger binding ability to dye-miR-1301-3p ( $-28.3$ ,  $-26.8$ , and  $-30.6$  kcal/mol, respectively). The competition assays proved the sequence-specific interactions between hsa-miR-1301-3p and its cognate

mRNA targets on *ADH6*, *ALDH5A1*, and *ALDH8A1*. The excess amount of unlabeled oligonucleotides for negative control failed to totally eliminate the densities of the miRNA:RNA complexes formed by dye-miR-1301-3p probe and its MREs in *ADH6* and *ALDH5A1*, respectively (**Figure 2a and 2b**, lane 4). The nonspecific competitor enhanced the miRNA:RNA complexes formed by dye-miR-1301-3p and dye-*ALDH8A1* oligonucleotides (**Figure 2c**, lane 4), however, the reasons for this enhancement remain to be elucidated (Wolfgang et al., 1997; Yu et al., 2018).

### **hsa-miR-1301-3p suppressed luciferase activity produced by MRE sequences derived from *ADH6*, *ALDH5A1*, and *ALDH8A1* 3'-UTRs**

Core sequences containing MREs or mutants within the MREs located at 3'-UTRs (**Figure 3a**) of *ADH6*, *ALDH5A1*, or *ALDH8A1* were introduced into luciferase reporter gene vectors and then transfected into 293T cells together with hsa-miR-1301-3p mimics, respectively. As shown in **Figure 3b**, hsa-miR-1301-3p mimics dramatically reduced reporter gene activity for constructs containing the MREs derived from the 3'-UTRs of *ADH6* (51.5%,  $P < 0.01$ ), *ALDH5A1* (38.9%,  $P < 0.01$ ), and *ALDH8A1* (37.3%,  $P < 0.01$ ), compared to that in cells treated with the miRNA negative control. Constructs containing mutated MREs for hsa-miR-1301-3p in *ADH6*, *ALDH5A1* and *ALDH8A1* (**Figure 3a**) were also transfected into 293T cells together with hsa-miR-1301-3p mimics; however, no inhibitory effects were observed. All these evidences proved that hsa-miR-1301-3p was able to bind to its MREs in *ADH6*, *ALDH5A1*, and *ALDH8A1* 3'-UTRs.

In addition, *ALDH5A1* was also predicted to be modulated by another five miRNAs, including hsa-miR-149-3p, hsa-miR-149-5p, hsa-miR-18a-5p, hsa-miR-330-5p, and



hsa-miR-93-3p. Among which, hsa-miR-330-5p and hsa-miR-149-3p exhibited the lower free energies of miRNA:mRNA duplexes (less than  $-30.0$  kcal/mol) compared to the other miRNAs, indicating their stronger abilities to bind to the corresponding MREs, respectively. To further validate the reliability of miRNA-gene interaction predictions, hsa-miR-330-5p was selected, and its interaction with *ALDH5A1* 3'-UTR was proved by both FREMSA and luciferase reporter gene assays (**Supplemental Figure 2**).

### **hsa-miR-1301-3p suppressed endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1* production in hepatic cells**

To investigate the regulatory roles of hsa-miR-1301-3p in the expression of endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1*, we transfected hsa-miR-1301-3p mimics or the miRNA negative control into HepG2 and Huh7 cells, and then measured the RNA and protein levels for *ADH6*, *ALDH5A1*, and *ALDH8A1* at 24h after transfection. Compared to HepG2 and Huh7 cells transfected with the miRNA negative control, cells transfected with hsa-miR-1301-3p mimics showed elevated levels of hsa-miR-1301-3p (**Figure 4a**). Importantly, qRT-PCR assays showed that mRNA levels for *ADH6*, *ALDH5A1*, and *ALDH8A1* were statistically significantly suppressed in HepG2 and Huh7 cells treated with ectopic hsa-miR-1301-3p (**Figure 4b**, 18%, 22%, and 33% in HepG2 cells, and **Figure 4c**, 34%, 37%, and 38% in Huh7 cells, respectively; all  $P < 0.05$ ). Likewise, Western blot assays showed that endogenous *ALDH5A1* and *ALDH8A1* protein levels were reduced in hepatic cells treated with exogenous hsa-miR-1301-3p (**Figure 4d**, *ALDH5A1* and *ALDH8A1* protein levels were 45% and 23% in HepG2 cells, and 29% and 60% in Huh7 cells,

respectively; all  $P < 0.05$ ). Although hsa-miR-1301-3p transfection suppressed ADH6 protein levels in HepG2 cells (23%,  $P < 0.05$ ), we were unable to demonstrate a statistically significant reduction in Huh7 cells, presumably due to reduced expression in this cell line under normal conditions.

### **hsa-miR-1301-3p suppressed ethanol-dependent induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* expression**

It is well known that *ADH* and *ALDH* genes are inducible by ethanol exposure. We then investigated whether ectopic hsa-miR-1301-3p can suppress the induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* by ethanol. As shown in **Figure 5a**, the cells exposed to 50 mM ethanol resulted in a reduction in the expression of endogenous hsa-miR-1301-3p (52% and 45% in HepG2 and Huh7 cells, respectively; both  $P < 0.05$ ), while the transfection of ectopic hsa-miR-1301-3p dramatically elevated the level of hsa-miR-1301-3p even under ethanol exposure.

The levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* mRNA transcripts were elevated upon ethanol exposure (1.19-fold, 1.35-fold, and 1.16-fold in HepG2 cells, and 1.18-fold, 1.33-fold, and 1.12-fold in Huh7 cells, respectively; all  $P < 0.05$ ), whereas they were statistically significantly decreased after transfection with hsa-miR-1301-3p mimics with ethanol exposure (decreased by 14%, 42%, and 13% in HepG2 cells, and 30%, 11%, and 17% in Huh7 cells, respectively; all  $P < 0.05$ )(**Figure 5b**). Similar regulatory trends were also observed in the protein levels for ADH6, ALDH5A1, and ALDH8A1, with the elevations upon ethanol exposure (1.62-fold, 1.27-fold, and 1.40-fold in HepG2 cells, and 1.37-fold for ALDH5A1, and 1.39-fold for ALDH8A1 in Huh7 cells, respectively; all  $P < 0.05$ ), and the reduction after transfection with hsa-miR-1301-3p

mimics and ethanol exposure (reduced by 29%, 22%, and 14% in HepG2 cells, and 25% for ALDH5A1, and 22% for ALDH8A1 in Huh7 cells, respectively; all  $P < 0.05$ )(**Figure 5c**).

---

## Discussion

ADHs and CYP2E1 catalyze the conversion of ethanol to acetaldehyde, and ALDHs catalyze the transformation of acetaldehyde to acetic acid, regulating the expression of these enzymes appropriately is vital for normal ethanol metabolism (Birley et al., 2009; Hartwell and Kranzler, 2019). The balance between the rates of accumulation and elimination of acetaldehyde (a known mutagen inducing DNA damage), is crucial for the pathological processes associated with ethanol-induced hepatotoxicity, ALDs, and liver cancer (Tan et al., 2017).

Based on the results from a previous study (Yang et al., 2013) and *in silico* analysis, ADHs and ALDHs were found to be variably expressed in the human population, consistent with inter-individual variability in alcohol and drug metabolism, and variable susceptibility toward ALDs among humans. Comprehensive mechanisms involved in the regulation of these enzymes are not fully understood, although it is presumed that genetic variations for *ADH*, *ALDHs*, and *CYP2E1* contribute to inter-individual variability in their expression among humans.

In this study, we applied a systematic approach using *in silico* bioinformatics methods to identify 11 miRNAs that could potentially regulate 2 *ADH* and 7 *ALDH* genes in human liver, based on *in silico* calculations of free energies of miRNAs binding to transcripts, and inverse correlations between the expression of these miRNAs and their putative target genes using data from a publicly available database. Of these 11 candidate regulatory miRNAs, hsa-miR-1301-3p was selected for focused study because the expression of this miRNA in human liver exhibited strong inverse correlations with the expression of several ethanol metabolizing genes. Our study

showed that hsa-miR-1301-3p suppresses the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes in human hepatic cells with or without ethanol exposure using a series of biochemical assays. These results provide new insight into the epigenetic regulation of ethanol metabolism.

More than 100 algorithms (Henry et al., 2014) have been developed to predict potential mRNA targets for regulation by miRNAs. However, the failure of carefully controlled experiments performed *in vitro* to confirm predicted miRNA/mRNA target regulatory interactions reveals current limitations of *in silico* miRNA target predictions made without experimental validation (Fan and Kurgan, 2015; Li and Zhang, 2015; Thomas et al., 2010). Over the past several years we have successfully characterized and confirmed the biochemical functions of many miRNAs in the regulation of DMETs (Chen et al., 2017; Jin et al., 2016; Knox et al., 2018; Wang et al., 2017; Yu et al., 2015a; Yu et al., 2015b; Yu et al., 2015c; Yu et al., 2018; Zeng et al., 2017) by integrating a combination of *in silico*, *in vitro*, and *in vivo* approaches to collect and analyze multiple layers of information.

In this study, *in silico* analyses predicted that 11 miRNAs, showing a high binding affinity with target sequences and a statistically significantly inverse correlation with their targets at the mRNA level, may potentially modulate 2 *ADHs* (*ADH4* and *ADH6*) and 7 *ALDHs* (*ALDH1A3*, *ALDH1B1*, *ALDH3A2*, *ALDH4A1*, *ALDH5A1*, *ALDH8A1*, and *ALDH9A1*) in the oxidative alcohol-aldehyde-acid metabolic pathway. Further, hsa-miR-1301-3p was selected for focused study because the expression of this miRNA in the human liver exhibited the strongest inverse correlations with the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes. Another important rationale

for the selection of hsa-miR-1301-3p is that we recognize the benefits of “killing many birds with one stone,” i.e., a specific miRNA affecting multiple target genes within the same pathway should have an increased regulatory efficiency over that pathway. This rationale could be physiologically or pharmacologically significant for the major substrates of ADH6, ALDH5A1, and ALDH8A1 enzymes, including ethanol, succinic semialdehyde, or 2-amino-muconic semialdehyde (Marchitti et al., 2008).

Our FREMSA results showed the direct interactions between hsa-miR-1301-3p and its cognate targets in *ADH6*, *ALDH5A1*, and *ALDH8A1* transcripts *in vitro*, and further competition assays and reporter gene assays proved the interactions were sequence-specific. Transfection assays showed that ectopic hsa-miR-1301-3p indeed suppressed endogenous ADH6, ALDH5A1, and ALDH8A1 production in liver cells. Together, our experimental evidence confirmed proved our prediction that hsa-miR-1301-3p interferes with the expression of these enzymes involved in alcohol and aldehyde metabolism.

Though some ADH and ALDH isoforms are inducible by alcohol and aldehyde; however, the functional significance of most ADH and ALDH enzymes in alcohol and aldehyde metabolism still needs to be elucidated. It was reported that the induction of class I ADH by ethanol involves liver transcriptional factors such as CCAAT/enhancer binding proteins (C/EBP)(He et al., 2002) and sterol regulatory element-binding protein-1c (SREBP-1c) (He et al., 2004). ADH6 may be regulated by hormonal changes or by exposure to xenobiotics due to the existence of glucocorticoid response elements (Yasunami et al., 1991) and other regulatory elements such as C/EBP $\alpha$  (Humphrey and Kuciauskas, 2006) in its promoter region,

but the induction of *ADH6* by alcohol has not been noted previously. Similarly, although some isoforms of human ALDH are inducible, no previous study reported that *ALDH5A1* and *ALDH8A1* are induced by ethanol. It is worth noting that ethanol can stimulate the expression of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes, which is in company with a statistically significant reduction of endogenous hsa-miR-1301-3p levels in HepG2 and Huh7 cells by ethanol exposure, suggesting that the induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* may be mediated by the suppression of hsa-miR-1301-3p. Excessive ectopic hsa-miR-1301-3p could inhibit the induction of *ADH6*, *ALDH5A1*, and *ALDH8A1* in liver cells, further echoing the suppression effect on *ADH6*, *ALDH5A1*, and *ALDH8A1* by hsa-miR-1301-3p.

*ADH6*, encoding a class V ADH, is mainly expressed in the liver. Many attempts to purify and characterize the human *ADH6* protein have failed. Although computational studies predicted distinct structural changes existing in *ADH6*, compared to other ADH enzymes (Fagerberg et al., 2014), recombinant human *ADH6* protein expressed in *E. coli* cells showed comparable properties with other ADH isozymes (Chen and Yoshida, 1991). Under our experimental conditions, *ADH6* protein was only detected in HepG2 cells but not in Huh7 cells, indicating that distinctive expression patterns are present in different human hepatic cell lines.

Both *ALDH5A1* and *ALDH8A1* belong to the superfamily of ALDHs. Besides metabolizing acetaldehyde (Davis et al., 2018; Muzio et al., 2012; Niimi et al., 2018), ALDHs were reported to modulate cell proliferation and differentiation by synthesizing retinoic acid, betaine, and  $\gamma$ -aminobutyric acid (Jackson et al., 2011). Deregulated *ALDH5A1* expression occurred in a variety of cancers (Tian et al., 2017). The knock-

out of the *ALDH5A1* gene in mice resulted in a significant reduction of glutathione, suggesting that *ALDH5A1* might be associated with mitochondrial function (Sauer et al., 2007). *ALDH8A1* was identified as a marker for liver diseases, including cirrhosis and liver cancer (Grinberg et al., 2014), but its functional significance still needs to be elucidated.

Our research strategy is associated with some limitations. First, we only focused on the miRNAs whose expression correlated inversely with the expression of ethanol metabolizing enzymes in human liver, which is considered as the classic regulatory mechanism for many miRNAs, i.e., a miRNA inhibits the expression of a target gene by binding to an MRE present in the 3'-UTR of the mRNA transcript. However, accumulating evidences proved that some miRNAs might increase gene expression by interacting with promoters, 5'-UTRs, and the protein-coding regions, involving different molecular mechanisms (Ning et al., 2019). Second, we employed a strict threshold ( $-20$  kcal/mol) for the free energy of binding between miRNA:RNA duplexes, which may result in the omission of some regulatory miRNAs that interact with targeting sequences via a non-seed-sequence-dependent manner (Piscioli et al., 1985). Third, it is well known that one miRNA may target multiple genes, while one gene may be targeted by multiple miRNAs. Therefore the overall effect of the 11 miRNAs, rather than one miRNA, may play an essential regulatory role in the metabolism of ethanol. In the future work, we would validate the regulatory effects of other 10 predicted miRNAs, and will measure the production of acetaldehyde and acetate, two useful benchmarks to test the activities of ADHs and ALDHs respectively, to evaluate the overall regulatory roles of multiple miRNAs.



In summary, we predicted 11 regulatory miRNAs that may target *ADH* and *ALDH* genes in human liver based on systematic bioinformatic analyses and *in vitro* and *in vivo* experiments. We identified hsa-miR-1301-3p as a new epigenetic factor involved in the regulation of the alcohol-aldehyde-acetate metabolism pathway by suppression of *ADH6*, *ALDH5A1*, and *ALDH8A1*. Our results provide a new clue to interpret the interactions between miRNAs and ethanol metabolism.

## Author Contributions

Participated in research design: Yu.

Conducted experiments: X Wang, Y Zhao, Luo, Xu, X Li, Y Wang, and Jin.

Performed data analysis: Chen, C Li, F, H, Q Zhao, J Zhao, Ning, and Zheng.

Wrote or contributed to the writing of the manuscript: X Wang, Y Zhao, Ning, and Yu.

## References

- Adachi M and Brenner DA (2005) Clinical syndromes of alcoholic liver disease. *Digestive diseases (Basel, Switzerland)* **23**(3-4): 255-263.
- Akoglu H (2018) User's guide to correlation coefficients. *Turkish journal of emergency medicine* **18**(3): 91-93.
- Birley AJ, James MR, Dickson PA, Montgomery GW, Heath AC, Martin NG and Whitfield JB (2009) ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. *Human molecular genetics* **18**(8): 1533-1542.
- Cederbaum AI (2012) Alcohol metabolism. *Clin Liver Dis* **16**(4): 667-685.
- Chen CS and Yoshida A (1991) Enzymatic properties of the protein encoded by newly cloned human alcohol dehydrogenase ADH6 gene. *Biochem Biophys Res Commun* **181**(2): 743-747.
- Chen Y, Zeng L, Wang Y, Tolleson WH, Knox B, Chen S, Ren Z, Guo L, Mei N, Qian F, Huang K, Liu D, Tong W, Yu D and Ning B (2017) The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. *Biochemical pharmacology* **145**: 178-191.
- Davis I, Yang Y, Wherrett D and Liu A (2018) Reassignment of the human aldehyde dehydrogenase ALDH8A1 (ALDH12) to the kynurenine pathway in tryptophan catabolism. **293**(25): 9594-9603.
- Davison JM, Mellott TJ, Kovacheva VP and Blusztajn JK (2009) Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain. *The Journal of biological chemistry* **284**(4):

1982-1989.

Dinis-Oliveira RJ (2016) Oxidative and Non-Oxidative Metabolomics of Ethanol. *Current drug metabolism* **17**(4): 327-335.

Dluzen DF and Lazarus P (2015) MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. *Drug metabolism reviews* **47**(3): 320-334.

Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpour S, Danielsson A, Edlund K, Asplund A, Sjostedt E, Lundberg E, Szigyaró CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F and Uhlen M (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Molecular & cellular proteomics : MCP* **13**(2): 397-406.

Fan X and Kurgan L (2015) Comprehensive overview and assessment of computational prediction of microRNA targets in animals. *Briefings in bioinformatics* **16**(5): 780-794.

Grinberg M, Stober RM, Edlund K, Rempel E, Godoy P, Reif R, Widera A, Madjar K, Schmidt-Heck W, Marchan R, Sachinidis A, Spitkovsky D, Hescheler J, Carmo H, Arbo MD, van de Water B, Wink S, Vinken M, Rogiers V, Escher S, Hardy B, Mitic D, Myatt G, Waldmann T, Mardinoglu A, Damm G, Seehofer D, Nussler A, Weiss TS, Oberemm A, Lampen A, Schaap MM, Luijten M, van Steeg H, Thasler WE, Kleinjans JC, Stierum RH, Leist M, Rahnenfuhrer J and Hengstler JG (2014)

- 
- Toxicogenomics directory of chemically exposed human hepatocytes. *Arch Toxicol* **88**(12): 2261-2287.
- Hartwell EE and Kranzler HR (2019) Pharmacogenetics of alcohol use disorder treatments: an update. *Expert opinion on drug metabolism & toxicology* **15**(7): 553-564.
- He L, Ronis MJ and Badger TM (2002) Ethanol induction of class I alcohol dehydrogenase expression in the rat occurs through alterations in CCAAT/enhancer binding proteins beta and gamma. *The Journal of biological chemistry* **277**(46): 43572-43577.
- He L, Simmen FA, Ronis MJ and Badger TM (2004) Post-transcriptional regulation of sterol regulatory element-binding protein-1 by ethanol induces class I alcohol dehydrogenase in rat liver. *The Journal of biological chemistry* **279**(27): 28113-28121.
- Henry VJ, Bandrowski AE, Pepin AS, Gonzalez BJ and Desfeux A (2014) OMICtools: an informative directory for multi-omic data analysis. *Database : the journal of biological databases and curation* **2014**.
- Heo MJ, Kim TH, You JS, Blaya D, Sancho-Bru P and Kim SG (2019) Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression. *Gut* **68**(4): 708-720.
- Humphrey JL and Kuciauskas D (2006) Charge transfer enhances two-photon absorption in transition metal porphyrins. *J Am Chem Soc* **128**(12): 3902-3903.
- Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW and Vasiliou V (2011) Update on the aldehyde dehydrogenase gene (ALDH) superfamily. *Hum*

*Genomics* **5**(4): 283-303.

Jelski W and Szmitkowski M (2008) Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. *Clin Chim Acta* **395**(1-2): 1-5.

Jiang J, Lee EJ, Gusev Y and Schmittgen TD (2005) Real-time expression profiling of microRNA precursors in human cancer cell lines. *Nucleic acids research* **33**(17): 5394-5403.

Jin Y, Yu D, Tolleson WH, Knox B, Wang Y, Chen S, Ren Z, Deng H, Guo Y and Ning B (2016) MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. *Biochemical pharmacology* **113**: 88-96.

Knox B, Wang Y, Rogers LJ, Xuan J, Yu D, Guan H, Chen J, Shi T, Ning B and Kadlubar SA (2018) A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression. *Environmental and molecular mutagenesis* **59**(2): 134-143.

Li Y and Zhang Z (2015) Computational Biology in microRNA. *Wiley interdisciplinary reviews RNA* **6**(4): 435-452.

Liangpunsakul S, Haber P and McCaughan GW (2016) Alcoholic Liver Disease in Asia, Europe, and North America. *Gastroenterology* **150**(8): 1786-1797.

Marchitti SA, Brocker C, Stagos D and Vasiliou V (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. *Expert opinion on drug metabolism & toxicology* **4**(6): 697-720.

McDaniel K, Herrera L, Zhou T, Francis H, Han Y, Levine P, Lin E, Glaser S, Alpini G and Meng F (2014) The functional role of microRNAs in alcoholic liver injury. *Journal of cellular and molecular medicine* **18**(2): 197-207.

- 
- Meng F, Glaser SS, Francis H, Yang F, Han Y, Stokes A, Staloch D, McCarra J, Liu J, Venter J, Zhao H, Liu X, Francis T, Swendsen S, Liu CG, Tsukamoto H and Alpini G (2012) Epigenetic regulation of miR-34a expression in alcoholic liver injury. *The American journal of pathology* **181**(3): 804-817.
- Miao L, Yao H, Li C, Pu M, Yao X, Yang H, Qi X, Ren J and Wang Y (2016) A dual inhibition: microRNA-552 suppresses both transcription and translation of cytochrome P450 2E1. *Biochimica et biophysica acta* **1859**(4): 650-662.
- Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y and Yokoi T (2010) Human CYP2E1 is regulated by miR-378. *Biochemical pharmacology* **79**(7): 1045-1052.
- Moss TJ and Wallrath LL (2007) Connections between epigenetic gene silencing and human disease. *Mutation research* **618**(1-2): 163-174.
- Muzio G, Maggiora M, Paiuzzi E, Oraldi M and Canuto RA (2012) Aldehyde dehydrogenases and cell proliferation. *Free radical biology & medicine* **52**(4): 735-746.
- Nakajima M and Yokoi T (2011) MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. *Pharmacology & therapeutics* **131**(3): 330-337.
- Niimi N, Yako H, Takaku S, Kato H, Matsumoto T, Nishito Y, Watabe K, Ogasawara S, Mizukami H, Yagihashi S, Chung SK and Sango K (2018) A spontaneously immortalized Schwann cell line from aldose reductase-deficient mice as a useful tool for studying polyol pathway and aldehyde metabolism. **144**(6): 710-722.
- Ning B, Yu D and Yu AM (2019) Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. *Biochemical*

- 
- pharmacology* **169**: 113638.
- Piscioli F, Scappini P and Luciani L (1985) Aspiration cytology in the staging of urologic cancer. *Cancer* **56**(5): 1173-1180.
- Rodenhiser D and Mann M (2006) Epigenetics and human disease: translating basic biology into clinical applications. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* **174**(3): 341-348.
- Sauer SW, Kolker S, Hoffmann GF, Ten Brink HJ, Jakobs C, Gibson KM and Okun JG (2007) Enzymatic and metabolic evidence for a region specific mitochondrial dysfunction in brains of murine succinic semialdehyde dehydrogenase deficiency (Aldh5a1<sup>-/-</sup> mice). *Neurochemistry international* **50**(4): 653-659.
- Song G and Wang L (2008) Transcriptional mechanism for the paired miR-433 and miR-127 genes by nuclear receptors SHP and ERRgamma. *Nucleic acids research* **36**(18): 5727-5735.
- Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, Constantinou S, Renaudin X, Lee M, Aebbersold R and Venkitaraman AR (2017) A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability. *Cell* **169**(6): 1105-1118.e1115.
- Thomas M, Lieberman J and Lal A (2010) Desperately seeking microRNA targets. *Nature structural & molecular biology* **17**(10): 1169-1174.
- Tian X, Han Y, Yu L, Luo B, Hu Z, Li X, Yang Z, Wang X, Huang W, Wang H, Zhang Q and Ma D (2017) Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer. *Cancer biology & therapy* **18**(4): 245-251.
- Tilg H and Day CP (2007) Management strategies in alcoholic liver disease. *Nature*



*clinical practice Gastroenterology & hepatology* **4**(1): 24-34.

Vasiliou V and Nebert DW (2005) Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. *Hum Genomics* **2**(2): 138-143.

Wang Y, Yu D, Tolleson WH, Yu LR, Green B, Zeng L, Chen Y, Chen S, Ren Z, Guo L, Tong W, Guan H and Ning B (2017) A systematic evaluation of microRNAs in regulating human hepatic CYP2E1. *Biochemical pharmacology* **138**: 174-184.

Wolfgang CD, Chen BP, Martindale JL, Holbrook NJ and Hai T (1997) gadd153/Chop10, a potential target gene of the transcriptional repressor ATF3. *Molecular and cellular biology* **17**(11): 6700-6707.

Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, Guo Y, Kaput J, Shi L and Ning B (2013) Gene expression variability in human hepatic drug metabolizing enzymes and transporters. *PLoS One* **8**(4): e60368.

Yasunami M, Chen CS and Yoshida A (1991) A human alcohol dehydrogenase gene (ADH6) encoding an additional class of isozyme. *Proc Natl Acad Sci U S A* **88**(17): 7610-7614.

Yu AM (2009) Role of microRNAs in the regulation of drug metabolism and disposition. *Expert opinion on drug metabolism & toxicology* **5**(12): 1513-1528.

Yu D, Chen S, Li D, Knox B, Guo L and Ning B (2020) FREMSA: A Method That Provides Direct Evidence of the Interaction between microRNA and mRNA. *Methods Mol Biol* **2102**: 557-566.

Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I and Ning B (2015a) Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. *Scientific reports* **5**: 8534.

- 
- Yu D, Green B, Tolleson WH, Jin Y, Mei N, Guo Y, Deng H, Pogribny I and Ning B (2015b) MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. *Biochemical pharmacology* **98**(1): 215-223.
- Yu D, Tolleson WH, Knox B, Jin Y, Guo L, Guo Y, Kadlubar SA and Ning B (2015c) Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells. *Biochemical pharmacology* **98**(4): 671-680.
- Yu D, Wu L, Gill P, Tolleson WH, Chen S, Sun J, Knox B, Jin Y, Xiao W, Hong H, Wang Y, Ren Z, Guo L, Mei N, Guo Y, Yang X, Shi L, Chen Y, Zeng L, Dreval K, Tryndyak V, Pogribny I, Fang H, Shi T, McCullough S, Bhattacharyya S, Schnackenberg L, Mattes W, Beger RD, James L, Tong W and Ning B (2018) Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. *Arch Toxicol* **92**(2): 845-858.
- Zeng L, Chen Y, Wang Y, Yu LR, Knox B, Chen J, Shi T, Chen S, Ren Z, Guo L, Wu Y, Liu D, Huang K, Tong W, Yu D and Ning B (2017) MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation. *Biochemical pharmacology* **140**: 139-149.

## Footnotes

Xubing Wang and Yanjie Zhao contributed equally to this work.

This study was supported and funded by the National Key Research and Development Program of China (SQ2017YFC1600201), National Natural Science Foundation of China (91743113, 81973075, and 81903354), and Young Taishan Scholars Program of Shandong Province (tsqn201812046).

Disclaimer: The information in this paper is not an official guidance or policy statement of the U.S. Food and Drug Administration (FDA). No official support or endorsement by the U.S. FDA is intended or should be inferred.

## Figure Legends

### Figure 1. Expression status of *ADH* (a) and *ALDH* (b) genes in a liver dataset obtained from the TCGA database.

RNA levels of 9 *ADH* and 15 *ALDH* genes were obtained from 98 liver tissues from the TCGA database. RPKM, reads per kilobase per million mapped reads.

**Figure 2. The hsa-miR-1301-3p interacted with *ADH6* (a), *ALDH5A1* (b), and *ALDH8A1* (c) mRNA *in vitro*.** Lanes 1 and 2 indicated the mobility of dye-miR-1301-3p and dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* oligonucleotides, respectively; lane 3 indicated the mobility status of the miRNA:mRNA complex formed by dye-miR-1301-3p oligonucleotides with dye-*ADH6*, dye-*ALDH5A1*, and dye-*ALDH8A1* mRNA oligonucleotides, respectively; lane 4 revealed the mobility shift status of miRNA:mRNA complex in the presence of excess unlabeled nonspecific competitors. NC, nonspecific competitor. The arrow, miRNA:mRNA complex; Hollow triangle, monomeric dye-miR-1301-3p; solid triangle, dimeric dye-miR-1301-3p; Experiments were carried out at least three times.

### Figure 3. The hsa-miR-1301-3p inhibited luciferase reporter gene expression.

**(a)** Free energy analyses of miRNA:mRNA duplex formed by hsa-miR-1301-3p and core or mutated response elements in 3'-UTRs of *ADH6*, *ALDH5A1*, and *ALDH8A1*, respectively, by the RNAhybrid algorithm. **(b)** Constructs containing the wildtype or mutated sequence of the core 3'-UTRs of *ADH6*, *ALDH5A1*, and *ALDH8A1* genes were transiently transfected into 293T cells, respectively, together with 50 nmol/L hsa-miR-1301-3p mimic or miRNA negative control. Cells were harvested at 24h after transfection. Three independent experiments were conducted in triplicate, and data

were shown as mean  $\pm$  SD.  $**P < 0.01$  versus miRNA negative control.

**Figure 4. The hsa-miR-1301-3p inhibited endogenous *ADH6*, *ALDH5A1*, and *ALDH8A1* expression in HepG2 cells and Huh7 cells.**

The hsa-miR-1301-3p mimics or miRNA negative control (both at the final concentration of 20 nmol/L) was transfected into HepG2 and Huh7 cells, respectively.

**(a)** The transfection of hsa-miR-1301-3p mimics dramatically elevated the hsa-miR-1301-3p levels in both HepG2 and Huh7 cells, compared to the transfection of miRNA negative control. Down-regulated mRNA levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* were observed after the transfection of hsa-miR-1301-3p mimics in **(b)** HepG2 or **(c)** Huh7 cells. **(d)** Protein levels of *ALDH5A1* and *ALDH8A1* were statistically significantly suppressed by exogenous hsa-miR-1301-3p mimics in both HepG2 and Huh7 cells. *ADH6* proteins were statistically significantly decreased by exogenous hsa-miR-1301-3p in HepG2 cells, while the detection of *ADH6* proteins failed in Huh7 cells, under our experimental conditions.

Each assay was carried out in triplicate, and data were shown as mean  $\pm$  SD. The fold changes of miRNA, mRNAs, and proteins induced by exogenous hsa-miR-1301-3p transfection, were calculated by defining their levels in the cells transfected with miRNA negative control (miR-NC) as 1.  $*P < 0.05$  versus miRNA negative control.  $**P < 0.01$  versus miRNA negative control.

**Figure 5. The hsa-miR-1301-3p suppressed ethanol-induced *ADH6*, *ALDH5A1*, and *ALDH8A1* expression in HepG2 and Huh7 cells. (a)** Ethanol exposure (at the final concentration of 50 mM) resulted in the reduction of endogenous hsa-miR-1301-3p levels in HepG2 and Huh7 cells.  $**P < 0.01$  versus untreated group.  $##P < 0.01$

versus ethanol-treatment group transfected with miRNA negative control.  $^{*}P < 0.05$  versus ethanol-treatment group transfected with hsa-miR-1301-3p mimics. **(b)** Exogenous hsa-miR-1301-3p was able to reduce the mRNA levels of *ADH6*, *ALDH5A1*, and *ALDH8A1* that increased by ethanol exposure in HepG2 and Huh7 cells.  $^{*}P < 0.05$  versus control group.  $^{#}P < 0.05$  and  $^{##}P < 0.01$  versus ethanol-treatment group transfected with miRNA negative control. **(c)** Exogenous hsa-miR-1301-3p was able to reduce the protein levels of ADH6, ALDH5A1, and ALDH8A1 that increased by ethanol exposure in HepG2 cells, and able to decrease the proteins of ALDH5A1 and ALDH8A1 that increased by ethanol exposure in Huh7 cells.  $^{*}P < 0.05$  and  $^{**}P < 0.01$  versus control group.  $^{#}P < 0.05$  versus ethanol-treatment group transfected with miRNA negative control. Each assay was performed in triplicate.

**Table 1. miRNAs potentially targeting *ADH* and *ALDH* genes**


<b>Gene symbol</b>	<b>Transcript</b>	<b>miRNA symbol</b>	<b>Targeting position</b>	<b>Free energy (kcal/mol)*</b>	<b>Correlation (r)<sup>#</sup></b>
<i>ALDH8A1</i>	NM_170771	hsa-miR-1301-3p	1911-1932	-30.6	-0.480
<i>ADH6</i>	NM_000672	hsa-miR-1301-3p	1274-1301	-28.3	-0.469
<i>ALDH5A1</i>	NM_001080	hsa-miR-1301-3p	1824-1845	-26.8	-0.459
<i>ALDH3A2</i>	NM_000382	hsa-miR-1301-3p	2681-2702	-26.8	-0.353
<i>ALDH5A1</i>	NM_001080	hsa-miR-149-3p	2074-2090	-33.0	-0.365
<i>ALDH4A1</i>	NM_003748	hsa-miR-149-3p	2619-2639	-28.6	-0.252
<i>ALDH5A1</i>	NM_001080	hsa-miR-149-5p	2512-2533	-24.4	-0.365
<i>ADH4</i>	NM_000670	hsa-miR-185-5p	1572-1593	-22.2	-0.270
<i>ALDH3A2</i>	NM_000382	hsa-miR-186-3p	2501-2522	-20.0	-0.256
<i>ALDH5A1</i>	NM_001080	hsa-miR-18a-5p	2015-2035	-22.0	-0.348
<i>ALDH5A1</i>	NM_001080	hsa-miR-330-5p	1835-1856	-26.3	-0.402
<i>ALDH5A1</i>	NM_001080	hsa-miR-330-5p	2008-2029	-32.5	-0.402
<i>ALDH4A1</i>	NM_003748	hsa-miR-330-5p	2636-2657	-22.4	-0.339
<i>ALDH1B1</i>	NM_000692	hsa-miR-532-3p	2943-2964	-23.6	-0.296
<i>ALDH4A1</i>	NM_003748	hsa-miR-766-3p	2393-2414	-35.2	-0.285
<i>ALDH4A1</i>	NM_003748	hsa-miR-766-3p	3059-3080	-30.0	-0.285
<i>ALDH5A1</i>	NM_001080	hsa-miR-93-3p	4543-4564	-22.7	-0.262
<i>ALDH9A1</i>	NM_000696	hsa-miR-93-5p	2314-2335	-25.2	-0.454
<i>ALDH1A3</i>	NM_000693	hsa-miR-93-5p	2361-2382	-25.5	-0.258

\*Calculated by the RNAhybrid program.


<sup>#</sup> All  $P < 0.05$ . The correlations between the expression of potential candidate miRNAs and the RNA levels of their cognate targeting genes based on the liver dataset from TCGA database were calculated by Pearson correlation analysis.

Figure 1

a




b






# Figure 2


a



b



c



# Figure 3

a

ADH6-WT	5' agGGUCG-UCCCUGCUGCAGAAGCUGUAu 3'	
	:   :                :	$\Delta G: -28.3 \text{ kcal/mol}$
hsa-miR-1301-3p	3' cuUCAGUGAGGGUC--CG---UCGACGUu 5'	
	:   :           :	$\Delta G: -19.3 \text{ kcal/mol}$
ADH6-Mut	5' agGGUCG-U <u>AAA</u> UGCUGCAGAAG <u>AAA</u> UAu 3'	
ALDH5A1-WT	5' --uGCCACGUGCCUGUGGCUGCAg 3'	
	:    :	$\Delta G: -26.8 \text{ kcal/mol}$
hsa-miR-1301-3p	3' cuuCAGUGAGGGUCCGUCGACGUu 5'	
	:    :	$\Delta G: -16.1 \text{ kcal/mol}$
ALDH5A1-Mut	5' --uGCCACGUGCCUGUG <u>AAA</u> GCAg 3'	
ALDH8A1-WT	5' -----gCCCAGGCGGUUGAGGCUGCAg 3'	
	:	$\Delta G: -30.6 \text{ kcal/mol}$
hsa-miR-1301-3p	3' cuucagugaGGGUCCG-----UCGACGUu 5'	
	:	$\Delta G: -19.8 \text{ kcal/mol}$
ALDH8A1-Mut	5' -----g <u>AAA</u> AGGCGGUUGAGG <u>AAA</u> CAg 3'	

b




Figure 4






Figure 5


a



b



c



## **Molecular Pharmacology**

**MicroRNA hsa-miR-1301-3p regulates human *ADH6*, *ALDH5A1* and *ALDH8A1* in the ethanol-acetaldehyde-acetate metabolic pathway**

Xubing Wang, Yanjie Zhao, Jiao Luo, Lin Xu, Xinmei Li, Yuan Jin,

Chuanhai Li, Meiyao Feng, Ying Wang, Jing Chen, Yufei Hou, Qianwen

Zhao, Jinquan Zhao, Baitang Ning, Yuxin zheng, and Dianke Yu

**Supplemental Table 1. Sequences of oligonucleotides and primers**

<b>Name</b>	<b>Sequence (5'—3')</b>
<i>For qRT-PCR</i>	
ADH6-F	CCTCCTGCAATGAGAGCTATGG
ADH6-R	GGATGTGCTGTCTGCTCTTCCA
ALDH5A1-F	AGGCTGGGATTTCCTTCAGGTGT
ALDH5A1-R	ACAGAGTTTGCTGCGTGGTGCA
ALDH8A1-F	ATCCACTGGTGAGCATAGGTGC
ALDH8A1-R	GAGGCTCAACTTATCCACTCCC
GAPDH-F	GAAATCCCATCACCATCTTCCAGG
GAPDH-R	GAGCCCCAGCCTTCTCCATG
hsa-miR-1301-3p-F	TTGCAGCTGCCTGGGAGTG
hsa-miR-1301-3p-R	CAGTGCGTGTCGTGGAGT
U6-F	CTCGCTTCGGCAGCACA
U6-R	AACGCTTCACGAATTTGCGT
<i>For FREMSA</i>	
dye-ADH6	AGGGUCGUCCCUGCUGCAGAAGCUGUAU
dye-ALDH5A1	UGCCACGUGCCUGUGGCUGCAG
dye-ALDH8A1	GCCCAGGCGGUUGAGGCUGCAG
dye-miR-1301-3p	UUGCAGCUGCCUGGGAGUGACUUC
dye-ALDH5A1-2008	CUACAGAACAUUGGGCCCAGAGC
dye-miR-330-5p	UCUCUGGGCCUGUGUCUUAGGC
miRNA negative control oligo	AACGCTTCACGAATTTGCGT

## **Supplemental Materials**

### **Oligonucleotides for FRMESA**

The RNA oligonucleotide for hsa-miR-330-5p was 5'-modified using DyLight 800 dye and named as dye-miR-330-5p, and the oligonucleotide corresponding to the MRE of hsa-miR-330-5p resident in *ALDH5A1* 3'-UTR was 5'-modified using Cy5.5 dye and designated as dye-ALDH5A1-2008.

### **Luciferase reporter gene construct**

The core sequence containing the MRE of hsa-miR330-5p in *ALDH5A1* 3'-UTR was synthesized chemically and subcloned into the pMirGlo system, and designated as ALDH5A1-WT-2008. The resultant construct was sequenced to confirm authenticity.

## Supplemental Figure Legends

### Supplemental Figure 1. Interactions among dye-miR-1301-3p

**oligonucleotides. (a)** Free energy analyses of miRNA:miRNA duplex formed by hsa-miR-1301-3p. **(b)** Time-dependent formation of the dimeric dye-miR-1301-3p. *Lanes* 1-4 indicated the mobility of monomeric and dimeric dye-miR-1301-3p with the incubation time of 0, 5, 10, and 20 min, respectively.

### Supplemental Figure 2. The hsa-miR-330-5p interacted with *ALDH5A1*


**3'-UTR. (a)** The hsa-miR-330-5p interacted with *ALDH5A1* mRNA *in vitro*. *Lanes* 1 and 2 indicated the mobility of dye-miR-330-5p and dye-*ALDH5A1*-2008, respectively; *lane* 3 indicated the mobility status of the miRNA:mRNA complex formed by dye-miR-330-5p with dye-*ALDH5A1*-2008 oligonucleotides; *lane* 4 revealed the mobility shift status of miRNA:mRNA complex in the presence of excess unlabeled nonspecific competitors. NC, nonspecific competitor. The arrow, miRNA:mRNA complex; solid triangle, dimeric dye-*ALDH5A1*-2008. **(b)** hsa-miR-330-5p suppressed luciferase activity produced by *ALDH5A1* 3'-UTR. Construct containing the core sequence of *ALDH5A1* 3'-UTR was transiently transfected into 293T cells, together with 50 nmol/L hsa-miR-330-5p mimic or miRNA negative control. Cells were harvested at 24h after transfection. Three independent experiments were conducted in triplicate, and data were shown as mean  $\pm$  SD. \* $P < 0.05$  versus miRNA negative control.




# Supplemental Figure 1

a

$\Delta G: -20.2 \text{ kcal/mol}$




b



# Supplemental Figure 2

a



b

